Drug developer Targacept (TRGT +0.6%) is down 82% from its 52-week high, but MKM Partners thinks...
Drug developer Targacept (TRGT +0.6%) is down 82% from its 52-week high, but MKM Partners thinks the stock could triple. The firm says TRGT has at least one thing going for it that most other biopharmas don't: multiple trials for multiple drugs with multiple indications. And even if none of them pan out, its cash balance makes it an attractive long-term play.
From other sites
at CNBC.com (Dec 13, 2011)
at CNBC.com (Nov 15, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs